Selecta Biosciences Stock Price, News & Analysis (NASDAQ:SELB)

$10.23 0.89 (9.53 %)
(As of 11/17/2017 05:28 AM ET)
Previous Close$9.34
Today's Range$9.43 - $10.56
52-Week Range$8.70 - $28.00
Volume476,993 shs
Average Volume110,778 shs
Market Capitalization$206.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences logoSelecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:SELB
  • CUSIP: N/A
  • Web: selectabio.com
Debt:
  • Debt-to-Equity Ratio: 0.32%
  • Current Ratio: 9.48%
  • Quick Ratio: 9.48%
Sales & Book Value:
  • Annual Sales: $8.08 million
  • Price / Sales: 28.28
  • Book Value: $2.91 per share
  • Price / Book: 3.52
Profitability:
  • Trailing EPS: ($3.10)
  • Net Income: ($36,210,000.00)
  • Net Margins: -1,918.59%
  • Return on Equity: -100.06%
  • Return on Assets: -61.41%
Misc:
  • Employees: 66
  • Outstanding Shares: 22,340,000
 

Frequently Asked Questions for Selecta Biosciences (NASDAQ:SELB)

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) issued its quarterly earnings results on Thursday, May, 11th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($1.22) by $0.40. The company earned $0.14 million during the quarter. Selecta Biosciences had a negative return on equity of 100.06% and a negative net margin of 1,918.59%. View Selecta Biosciences' Earnings History.

Where is Selecta Biosciences' stock going? Where will Selecta Biosciences' stock price be in 2017?

3 Wall Street analysts have issued 12 month price targets for Selecta Biosciences' shares. Their predictions range from $28.00 to $32.00. On average, they expect Selecta Biosciences' share price to reach $30.00 in the next twelve months. View Analyst Ratings for Selecta Biosciences.

What are Wall Street analysts saying about Selecta Biosciences stock?

Here are some recent quotes from research analysts about Selecta Biosciences stock:

  • 1. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (11/11/2017)
  • 2. Canaccord Genuity analysts commented, "We recommend investors BUY SELB shares on weakness following updated Phase 2 data for SEL-212. The SVP particle can simply always be dosed in combination with pegsiticase to control uric acid, versus the Phase 2 where some patients showed a loss of serum uric acid control when SVP+pegsiticase was given first, and then followed by pegsiticase alone. The ongoing Phase 2 trial continues to show dose-dependent serum uric acid (SUA) suppression with higher doses of SVP-rapamycin, a positive, in our view. Currently, SELB is still enrolling patients for the higher SVP-rapamycin dose cohort (0.125 or 0.15 mg/kg SVP-rapamycin + 0.4 mg/kg pegsiticase), with 10 subjects per cohort expected." (11/7/2017)
  • 3. Needham & Company LLC analysts commented, "Selecta presented initial Phase II multi-dose data for SEL-212 on its 4Q16 earnings call. We believe this early data is very encouraging as a clinically active monthly dose appears to have been reached. Dosing continues with 2 additional cohorts. The next update is expected at a conference in June. We remain buyers of SELB as we believe they have both a promising clinical candidate in SEL-212 and a broadly applicable platform to induce tolerance to anti-drug antibodies." (3/28/2017)

Who are some of Selecta Biosciences' key competitors?

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the folowing people:

  • Werner Cautreels Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 64)
  • Omid Farokhzad M.D., Co-Founder, Director (Age 48)
  • John H. Leaman M.D., Chief Financial Officer, Principal Accounting Officer, Head of Corporate Strategy and Treasurer (Age 45)
  • Lloyd Johnston Ph.D., Chief Operating Officer, Senior Vice President - Research & development (Age 49)
  • Takashi Kei Kishimoto Ph.D., Chief Scientific Officer (Age 57)
  • David Abraham J.D., Chief Compliance Officer, General Counsel, Corporate Secretary (Age 51)
  • Peter Keller, Chief Business Officer (Age 46)
  • Dmitry Ovchinnikov, Managing Director, SelectaRUS, LLC
  • Earl Sands M.D., Chief Medical Officer (Age 59)
  • Carl L. Gordon Ph.D., Director (Age 52)

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Who owns Selecta Biosciences stock?

Selecta Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (5.20%), JPMorgan Chase & Co. (1.63%), Candriam Luxembourg S.C.A. (0.65%), Bank of New York Mellon Corp (0.19%) and Schwab Charles Investment Management Inc. (0.13%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Abraham, David Siewers, Edwin M Kania, Jr, Lloyd P Johnston, Nanodimension Management Ltd, Peter Keller, Takashi Kei Kishimoto, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Institutional Ownership Trends for Selecta Biosciences.

Who bought Selecta Biosciences stock? Who is buying Selecta Biosciences stock?

Selecta Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Candriam Luxembourg S.C.A., Schwab Charles Investment Management Inc., Bank of New York Mellon Corp and JPMorgan Chase & Co.. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Nanodimension Management Ltd, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Insider Buying and Selling for Selecta Biosciences.

How do I buy Selecta Biosciences stock?

Shares of Selecta Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Selecta Biosciences' stock price today?

One share of Selecta Biosciences stock can currently be purchased for approximately $10.23.

How big of a company is Selecta Biosciences?

Selecta Biosciences has a market capitalization of $206.17 million and generates $8.08 million in revenue each year. The company earns ($36,210,000.00) in net income (profit) each year or ($3.10) on an earnings per share basis. Selecta Biosciences employs 66 workers across the globe.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 480 Arsenal Way, WATERTOWN, MA 02472-2891, United States. The company can be reached via phone at +1-617-9231400 or via email at [email protected]


MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  163
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Selecta Biosciences (NASDAQ:SELB)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.00 (193.26% upside)

Consensus Price Target History for Selecta Biosciences (NASDAQ:SELB)

Price Target History for Selecta Biosciences (NASDAQ:SELB)

Analysts' Ratings History for Selecta Biosciences (NASDAQ:SELB)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017Canaccord GenuityReiterated RatingBuy$30.00N/AView Rating Details
3/28/2017Needham & Company LLCReiterated RatingBuy$28.00HighView Rating Details
12/8/2016Stifel NicolausReiterated RatingBuy$23.00 -> $32.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Selecta Biosciences (NASDAQ:SELB)

Earnings by Quarter for Selecta Biosciences (NASDAQ:SELB)

Earnings History by Quarter for Selecta Biosciences (NASDAQ SELB)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/11/2017Q2 2017($0.86)($0.85)$0.03 millionViewN/AView Earnings Details
5/11/2017Q1 2017($1.22)($0.82)$0.14 millionViewN/AView Earnings Details
3/27/201712/31/2016($0.25)($0.77)$15.00 million$2.93 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Selecta Biosciences (NASDAQ:SELB)
Current Year EPS Consensus Estimate: $-2.25 EPS
Next Year EPS Consensus Estimate: $-2.84 EPS

Dividends

Dividend History for Selecta Biosciences (NASDAQ:SELB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Selecta Biosciences (NASDAQ SELB)

Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 53.03%
Insider Trades by Quarter for Selecta Biosciences (NASDAQ:SELB)
Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)

Insider Trades by Quarter for Selecta Biosciences (NASDAQ SELB)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/14/2017Timothy A SpringerDirectorBuy57,598$9.27$533,933.46View SEC Filing  
11/13/2017Werner CautreelsInsiderBuy20,000$9.31$186,200.00View SEC Filing  
11/10/2017Timothy C BarabeDirectorBuy5,000$9.37$46,850.00View SEC Filing  
9/26/2017Amir NashatDirectorSell70,226$18.91$1,327,973.66View SEC Filing  
9/25/2017Amir NashatDirectorSell79,211$19.13$1,515,306.43View SEC Filing  
9/21/2017Amir NashatDirectorSell147,187$19.91$2,930,493.17View SEC Filing  
9/20/2017Amir NashatDirectorSell42,610$20.03$853,478.30View SEC Filing  
9/20/2017David SiewersCFOSell16,424$20.00$328,480.00View SEC Filing  
7/3/2017Lloyd P JohnstonCOOSell5,959$19.10$113,816.90View SEC Filing  
6/30/2017David SiewersCFOSell7,420$20.00$148,400.00View SEC Filing  
6/29/2017David SiewersCFOSell9,652$20.00$193,040.00View SEC Filing  
6/27/2017Peter KellerInsiderSell4,595$19.30$88,683.50View SEC Filing  
6/27/2017Timothy A SpringerDirectorBuy338,791$17.71$5,999,988.61View SEC Filing  
6/26/2017David SiewersCFOSell6,886$20.00$137,720.00View SEC Filing  
6/15/2017Lloyd P JohnstonCOOSell20,512$17.00$348,704.00View SEC Filing  
6/1/2017Timothy A SpringerDirectorBuy518$13.75$7,122.50View SEC Filing  
5/18/2017Timothy A SpringerDirectorBuy16,104$14.00$225,456.00View SEC Filing  
5/16/2017Edwin M. Kania, Jr.DirectorSell266,795$14.00$3,735,130.00View SEC Filing  
4/17/2017Lloyd P JohnstonCOOSell13,205$13.95$184,209.75View SEC Filing  
12/28/2016Takashi Kei KishimotoInsiderSell10,000$17.55$175,500.00View SEC Filing  
12/21/2016David AbrahamInsiderSell14,844$18.00$267,192.00View SEC Filing  
12/19/2016Peter KellerInsiderSell4,723$18.58$87,753.34View SEC Filing  
6/27/2016Amir NashatDirectorBuy150,000$14.00$2,100,000.00View SEC Filing  
6/27/2016Nanodimension Management LtdMajor ShareholderBuy385,000$14.00$5,390,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Selecta Biosciences (NASDAQ:SELB)

Latest Headlines for Selecta Biosciences (NASDAQ SELB)

Source:
DateHeadline
Insider Buying: Selecta Biosciences, Inc. (SELB) Director Purchases 57,598 Shares of StockInsider Buying: Selecta Biosciences, Inc. (SELB) Director Purchases 57,598 Shares of Stock
www.americanbankingnews.com - November 16 at 8:10 PM
Selecta Biosciences, Inc. (SELB) Insider Acquires $186,200.00 in StockSelecta Biosciences, Inc. (SELB) Insider Acquires $186,200.00 in Stock
www.americanbankingnews.com - November 14 at 10:34 PM
Timothy C. Barabe Buys 5,000 Shares of Selecta Biosciences, Inc. (SELB) StockTimothy C. Barabe Buys 5,000 Shares of Selecta Biosciences, Inc. (SELB) Stock
www.americanbankingnews.com - November 13 at 7:52 PM
Selecta Biosciences, Inc. (SELB) Upgraded to "Buy" by Zacks Investment ResearchSelecta Biosciences, Inc. (SELB) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 11 at 6:30 AM
Selecta Biosciences Enters Oversold Territory (SELB)Selecta Biosciences Enters Oversold Territory (SELB)
www.thestreet.com - November 9 at 6:13 PM
Edited Transcript of SELB earnings conference call or presentation 7-Nov-17 1:30pm GMTEdited Transcript of SELB earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 1:12 PM
Selecta Biosciences, Inc. (SELB) Downgraded to "Neutral" at UBS AGSelecta Biosciences, Inc. (SELB) Downgraded to "Neutral" at UBS AG
www.americanbankingnews.com - November 9 at 10:54 AM
Selecta Biosciences (SELB) "Buy" Rating Reiterated at Canaccord GenuitySelecta Biosciences' (SELB) "Buy" Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - November 7 at 12:08 PM
Selecta Biosciences, Inc. to Host Earnings CallSelecta Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 10:04 AM
Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate UpdateSelecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 10:04 AM
Selecta Biosciences, Inc. (SELB) Receives Average Recommendation of "Buy" from AnalystsSelecta Biosciences, Inc. (SELB) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 2 at 9:44 PM
Selecta Biosciences, Inc. (SELB) Scheduled to Post Quarterly Earnings on WednesdaySelecta Biosciences, Inc. (SELB) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
-$0.88 EPS Expected for Selecta Biosciences, Inc. (SELB) This Quarter-$0.88 EPS Expected for Selecta Biosciences, Inc. (SELB) This Quarter
www.americanbankingnews.com - October 31 at 11:08 PM
Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017
feeds.benzinga.com - October 31 at 8:50 AM
Selecta Biosciences Announces Important Additions to Senior Leadership TeamSelecta Biosciences Announces Important Additions to Senior Leadership Team
finance.yahoo.com - October 27 at 5:02 PM
Selecta Biosciences, Inc. (SELB) PT Raised to $30.00Selecta Biosciences, Inc. (SELB) PT Raised to $30.00
www.americanbankingnews.com - October 12 at 10:38 PM
Selecta Biosciences, Inc. (SELB) Upgraded at Zacks Investment ResearchSelecta Biosciences, Inc. (SELB) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 12 at 6:20 AM
Selecta Biosciences, Inc. (SELB) Given Consensus Rating of "Hold" by BrokeragesSelecta Biosciences, Inc. (SELB) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 8 at 6:38 PM
Selecta Biosciences Announces Upcoming Clinical and Scientific PresentationsSelecta Biosciences Announces Upcoming Clinical and Scientific Presentations
finance.yahoo.com - October 6 at 9:21 AM
Selecta Biosciences, Inc. (SELB) Director Sells $1,327,973.66 in StockSelecta Biosciences, Inc. (SELB) Director Sells $1,327,973.66 in Stock
www.americanbankingnews.com - September 28 at 7:24 PM
Insider Selling: Selecta Biosciences, Inc. (SELB) Director Sells 79,211 Shares of StockInsider Selling: Selecta Biosciences, Inc. (SELB) Director Sells 79,211 Shares of Stock
www.americanbankingnews.com - September 26 at 7:24 PM
David Siewers Sells 16,424 Shares of Selecta Biosciences, Inc. (SELB) StockDavid Siewers Sells 16,424 Shares of Selecta Biosciences, Inc. (SELB) Stock
www.americanbankingnews.com - September 22 at 7:52 PM
Insider Selling: Selecta Biosciences, Inc. (SELB) Director Sells 42,610 Shares of StockInsider Selling: Selecta Biosciences, Inc. (SELB) Director Sells 42,610 Shares of Stock
www.americanbankingnews.com - September 22 at 7:32 PM
Selecta Biosciences, Inc. (SELB) Director Sells $2,930,493.17 in StockSelecta Biosciences, Inc. (SELB) Director Sells $2,930,493.17 in Stock
www.americanbankingnews.com - September 22 at 7:30 PM
Selecta Biosciences to Participate in Upcoming Investor ConferencesSelecta Biosciences to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 20 at 8:54 AM
Selecta Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : SELB-US : September 13, 2017Selecta Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : SELB-US : September 13, 2017
finance.yahoo.com - September 14 at 9:53 AM
Selecta Biosciences, Inc. (SELB) Receives Consensus Rating of "Buy" from AnalystsSelecta Biosciences, Inc. (SELB) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 13 at 8:54 PM
Selecta Biosciences, Inc. (SELB) Expected to Announce Earnings of -$0.88 Per ShareSelecta Biosciences, Inc. (SELB) Expected to Announce Earnings of -$0.88 Per Share
www.americanbankingnews.com - September 5 at 2:14 PM
Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017
finance.yahoo.com - September 2 at 8:36 AM
Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017
finance.yahoo.com - September 2 at 8:36 AM
Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 12:33 PM
Selecta Biosciences, Inc. (SELB) Given Consensus Recommendation of "Buy" by BrokeragesSelecta Biosciences, Inc. (SELB) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 19 at 6:50 PM
Selecta Biosciences, Inc. – Value Analysis (NASDAQ:SELB) : August 15, 2017Selecta Biosciences, Inc. – Value Analysis (NASDAQ:SELB) : August 15, 2017
finance.yahoo.com - August 15 at 9:32 PM
Selecta Biosciences, Inc. (NASDAQ:SELB) Issues Quarterly  Earnings ResultsSelecta Biosciences, Inc. (NASDAQ:SELB) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 12 at 10:40 AM
Edited Transcript of SELB earnings conference call or presentation 11-Aug-17 12:30pm GMTEdited Transcript of SELB earnings conference call or presentation 11-Aug-17 12:30pm GMT
finance.yahoo.com - August 12 at 7:44 AM
Selecta Biosciences (NASDAQ:SELB) Buy Rating Reaffirmed at Canaccord GenuitySelecta Biosciences' (NASDAQ:SELB) Buy Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - August 11 at 6:20 PM
Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate UpdateSelecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 11 at 8:23 AM
Selecta Biosciences to Report Second Quarter 2017 Financial Results on Friday, August 11, 2017Selecta Biosciences to Report Second Quarter 2017 Financial Results on Friday, August 11, 2017
finance.yahoo.com - August 5 at 6:58 AM
Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2017Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2017
finance.yahoo.com - August 2 at 4:19 PM
Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : August 1, 2017Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : August 1, 2017
finance.yahoo.com - August 1 at 3:44 PM
 Brokerages Expect Selecta Biosciences, Inc. (NASDAQ:SELB) to Announce -$0.86 Earnings Per Share Brokerages Expect Selecta Biosciences, Inc. (NASDAQ:SELB) to Announce -$0.86 Earnings Per Share
www.americanbankingnews.com - July 30 at 10:04 PM
Selecta Biosciences, Inc. (NASDAQ:SELB) Receives Consensus Rating of "Buy" from BrokeragesSelecta Biosciences, Inc. (NASDAQ:SELB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 25 at 8:40 PM
Selecta Biosciences, Inc. (NASDAQ:SELB) COO Lloyd P. Johnston Sells 5,959 SharesSelecta Biosciences, Inc. (NASDAQ:SELB) COO Lloyd P. Johnston Sells 5,959 Shares
www.americanbankingnews.com - July 6 at 8:04 PM
-$0.86 Earnings Per Share Expected for Selecta Biosciences, Inc. (NASDAQ:SELB) This Quarter-$0.86 Earnings Per Share Expected for Selecta Biosciences, Inc. (NASDAQ:SELB) This Quarter
www.americanbankingnews.com - July 6 at 6:20 PM
Insider Selling: Selecta Biosciences, Inc. (NASDAQ:SELB) CFO Sells 7,420 Shares of StockInsider Selling: Selecta Biosciences, Inc. (NASDAQ:SELB) CFO Sells 7,420 Shares of Stock
www.americanbankingnews.com - July 5 at 7:44 PM
Selecta Biosciences (SELB) Reports $50M Private Placement of Common StockSelecta Biosciences (SELB) Reports $50M Private Placement of Common Stock
www.streetinsider.com - June 27 at 8:13 AM
Selecta Biosciences (SELB) Commences Dosing in Phase 1 Trial of Nicotine Vaccine for Smoking CessationSelecta Biosciences (SELB) Commences Dosing in Phase 1 Trial of Nicotine Vaccine for Smoking Cessation
www.streetinsider.com - May 12 at 1:14 AM
Ready for Launch: Selecta Biosciences Inc. Jumps as Much as 16%Ready for Launch: Selecta Biosciences Inc. Jumps as Much as 16%
www.fool.com - May 2 at 5:22 PM
After-Hours Stock Movers 03/27: (PSIX) (OCN) (RHT) Higher; (CYRX) (EVH) (STOR) Lower (more...)After-Hours Stock Movers 03/27: (PSIX) (OCN) (RHT) Higher; (CYRX) (EVH) (STOR) Lower (more...)
www.streetinsider.com - March 28 at 9:27 AM
FDA Nod For TSRO, Déjà Vu For ARQL, FOMX Plunges On Trial Data, SELB AbuzzFDA Nod For TSRO, Déjà Vu For ARQL, FOMX Plunges On Trial Data, SELB Abuzz
www.rttnews.com - March 28 at 9:27 AM

Social Media

Financials

Chart

Selecta Biosciences (NASDAQ SELB) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.